Turnover of ¹³¹I-Fibrinogen in Mercury Chloride Intoxicated Dogs^[*]

Summary

The turnover of ¹³¹I-fibrinogen, studied in 15 normal dogs, amounted on the average to 2.6 days. The fibrinogen level considerably increased but the biological half-life time of ¹³¹I-fibrinogen was significantly shorter in mercury chloride intoxicated dogs, particularly in the first phase of intoxication.

It has been concluded that the fibrinolytic enzymes connected with kidney and depleted in intoxicated dogs are not essential for the fibrinogen catabolism. The elevation of fibrinogen in mercury chloride intoxication is not directly caused by the inhibition of fibrinolytic enzymes.

Possible explanations of the accelerated turnover of fibrinogen in HgCl₂ treated dogs were discussed.

^* Aided in part by the grants from the Biochemical and Biophysical Committee, Dept. II and from Dept. VI, Polish Academy of Sciences.

• References

• 1 Adelson E, Rheingold J. J, Parker O, Buenaventura A, Crosby W. H. Platelet and fibrinogen survival in normal and abnormal states of coagulation. Blood 17: 267 1961;
• 2 Amris A, Amris C. J. Turnover and distribution of iodine labelled human fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg) 11: 404 1964;
• 3 Astrup T, Sterndorff I. Fibrinolysokinase activity in animal and human tissue. Acta physiol, scand 37: 41 1956;
• 4 Attencio A. G, Burdick D. G, Reeve E. B. An accurate isotope dilution method for measuring plasma fibrinogen. J. Lab. clin. Med. 66: 137 1965;
• 5 Attencio A. C, Reeve E. B. Studies on the metabolism and distribution of fibrinogen in young and older-rabbits. II. Results. J. Lab. clin. Med. 66: 20 1965;
• 6 Blombäck B, Carlson L. A, ranzen S. F, Zetterquist E. Turnover of ¹³¹I-labelled fibrinogen in man. Acta med. scand. 179: 557 1966;
• 7 Buluk K, Furman M. On the controlling function of the kidneys in fibrinolysis. Experientia (Basel) 18: 146 1962;
• 8 Buluk K, Matofiejew M. Otrzymywanie aktywatora fibrynolizy w nerce poza ustrojem (aktywator fibrynolizy w izolowanej nerce. Acta physiol, pol. 14: 371 1963;
• 9 Budzynski A. Doctor Thesis. Institute of Nuclear Research; Warsaw: 1962
• 10 Devakul K, Harinasuta T, Reid H. A. ¹²⁵I-labelled fibrinogen in cerebral malaria. Lancet II: 886 1966;
• 11 Egeberg O. Blood coagulation in renal failure. Scand. J. clin. Lab. Invest 14: 163 1962;
• 12 Gajewski J, Alexander B. Effect of epsilon-aminocaproic acid on the turnover of labelled fibrinogen in rabbits. Circulât. Res. 13: 432 1963;
• 13 Gross R, Nieth H, Mammen E. Blutungsbereitschaft und Gerinnungsstörungen bei Urämie. Klin. Wschr. 36: 107 1958;
• 14 Hart H Ch. The biological half-life of ¹³¹I-fibrinogen in “Genetics and interaction of blood clotting factors”. 121 F. K. Schattauer; Stuttgart: 1965
• 15 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Biochem. J. 60: 671 1955;
• 16 Koffler D, Paronetto F. Immunofluorescent localization of immunoglobulins, complement and fibrinogen in human disease. II. Acute, subacute and chronic glomerulonephritis. J. clin. Invest 44: 1665 1965;
• 17 Bidstrup PLesley. Toxicity of mercury and its compounds. Elsevier: Amsterdam; 1964
• 18 Lewis J. H. Effects of epsilon-aminocaproic acid on survival of fibrinogen-¹³¹I and fibrinolytic and coagulation factors in dogs. Proc. Soc. exp. Biol. (N. Y) 114: 111 1963;
• 19 Lewis J. H, Ferguson E. E, Schoenfeld C. Studies concerning the turnover of fibrinogen-¹³¹I in the dog. J. Lab. clin. Med. 58: 247 1961;
• 20 Lewis J. H, Zucker M. B, Ferguson J. H. Bleeding tendency in uremia. Blood 11: 1073 1965;
• 21 Madden R. E, Gould R. G. Turnover rate of plasma fibrinogen. Fed. Proc. 11: 252 1952;
• 22 McConnell P, Johnson J. G, Young I, Holemans R. Localization of plasminogen activator in kidney tissue. Lab. Invest 15: 980 1966;
• 23 McFarlane A. S, Todd D, Cromvell S. Fibrinogen degradation in humans. Clin. Sci. 26: 415 1964;
• 24 Niewiarowski S, Prokopowicz J, Poplawski A, Worowski K. Inhibition of dog fibrinolytic system in experimental tubular necrosis of kidney. Experientia (Basel) 02: 99 1964;
• 25 Nowak A, Zahorska-Markiewicz B. Aktywnosc urokinazy i fibrynoliza w chorobach nerek. Pol. Arch. Med. wewnet. 35: 653 1965;
• 26 Prokopowicz J, Rejniak L, Niewiarowski S, Worowski K. Fibrinolytic activity of tissue sections of dog kidney. Thrombos. Diathes. haemorrh. (Stuttg) 12: 396 1964;
• 27 Quick A. J. The physiology and pathology of haemostasis. Kimpton, London: 1951
• 28 Rausen A. R, Cruchaud A, McMillan G. W, Gitlin D. A study of fibrinogen turnover in classical hemophilia and congenital afibrinogenemia. Blood 18: 710 1961;
• 29 Rogoeczi E, Rogoeczi G. E, McFarlane A. S. Relation between rate of catabolism, plasma concentration and pool size of fibrinogen. Pflügers Arch. ges. Physiol. 279: 17 1964;
• 30 Regoeczi E. L, Henley G. E, Holloway R. C, McFarlane A. S. Turnover of ¹³¹I-labelled fibrinogen in fever. Brit. J. exp. Path. 44: 397 1963;
• 31 Regoeczi E, Gergely J, McFarlane A. S. In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-¹³¹I. J. clin. Invest 45: 1202 1966;
• 32 Schultz F. H. Das Fibrinogen. VEB Georg Thieme; Leipzig: 1953
• 33 Takeda Y, Reeve E. B. Fibrinogen metabolism in patients with rheumatoid arthritis. Fed. Proc. 42: 386 1965;
• 34 Truax W. E, McCoy J. Gamma globulin catabolism by the kidney. Tex. Rep. Biol. Med. 23: 793 1965;
• 35 Vassalli P, Morris R. H, McCluskey R. T. The pathogenic role of fibrin deposition in the glomerular lesions of toxemia of pregnancy. J. exp. Med. 118: 467 1963;
• 36 Vassalli P, McCluskey R. T. Editorial. The coagulation process and glomerular disease. Amer. J. Med. 39: 179 1965;
• 37 Wiliams J. R. B. The fibrinolytic activity of urine. Brit. J. exp. Path. 32: 530 1951;
• 38 Worowski K. Unpublished results..
• 39 Worowski K, Niewiarowski S, Prokopowicz J. Fibrinolysis and fibrinogen breakdown products (antithrombin VI) in renal venous blood (RVB) in dog. Thrombos. Diathes. haemorrh. (Stuttg) 12: 87 1964;